MX2022010801A - Combinaciones. - Google Patents

Combinaciones.

Info

Publication number
MX2022010801A
MX2022010801A MX2022010801A MX2022010801A MX2022010801A MX 2022010801 A MX2022010801 A MX 2022010801A MX 2022010801 A MX2022010801 A MX 2022010801A MX 2022010801 A MX2022010801 A MX 2022010801A MX 2022010801 A MX2022010801 A MX 2022010801A
Authority
MX
Mexico
Prior art keywords
inhibitors
compound
pharmaceutically acceptable
along
acceptable salts
Prior art date
Application number
MX2022010801A
Other languages
English (en)
Inventor
Kevin Duane Bunker
Joseph Robert Pinchman
Fernando Donate
Peter Qinhua Huang
Ahmed Abdi Samatar
Hooman Izadi
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of MX2022010801A publication Critical patent/MX2022010801A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Glass Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente descripción se describen terapias de combinación de inhibidores de Bcl-2 (Compuesto (A), junto con sales farmacéuticamente aceptables de este) e inhibidores de CDK 4/6 (Compuesto (B), junto con sales farmacéuticamente aceptables de este) para tratar una enfermedad o afección, tal como un cáncer, incluidos cáncer de mama y leucemia.
MX2022010801A 2020-05-07 2021-05-05 Combinaciones. MX2022010801A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063021290P 2020-05-07 2020-05-07
PCT/US2021/030931 WO2021226263A1 (en) 2020-05-07 2021-05-05 Combinations

Publications (1)

Publication Number Publication Date
MX2022010801A true MX2022010801A (es) 2022-11-30

Family

ID=78468359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010801A MX2022010801A (es) 2020-05-07 2021-05-05 Combinaciones.

Country Status (11)

Country Link
US (1) US20230158048A1 (es)
EP (1) EP4106760A4 (es)
JP (1) JP2023525022A (es)
KR (1) KR20230007360A (es)
CN (1) CN115666574A (es)
AU (1) AU2021268195A1 (es)
CA (1) CA3174700A1 (es)
IL (1) IL297960A (es)
MX (1) MX2022010801A (es)
TW (1) TW202207920A (es)
WO (1) WO2021226263A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7114478B2 (ja) * 2016-03-28 2022-08-08 プレサージュ バイオサイエンシズ，インコーポレイテッド 癌の治療のための配合剤
KR20200108302A (ko) * 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
WO2019200224A1 (en) * 2018-04-13 2019-10-17 The Broad Institute, Inc. Synergistic drug combinations predicted from genomic features and single-agent response profiles
JP6916969B1 (ja) * 2018-06-21 2021-08-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ３−（（１Ｒ，３Ｒ）−１−（２，６−ジフルオロ−４−（（１−（３−フルオロプロピル）アゼチジン−３−イル）アミノ）フェニル）−３−メチル−１，３，４，９−テトラヒドロ−２Ｈ−ピリド［３，４−ｂ］インドール−２−イル）−２，２−ジフルオロプロパン−１−オールの固体形態及び置換されたフェニル又はピリジニル部分を含む縮合三環式化合物を調製するための方法とそれらの使用方法
CN111214471B (zh) * 2018-11-23 2021-04-02 苏州亚盛药业有限公司 药物组合物及其用途
EP3972601A4 (en) * 2019-07-10 2023-07-12 Recurium IP Holdings, LLC BCL-2 INHIBITOR NANOPARTICLE FORMULATION
CA3165468A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
WO2022133446A1 (en) * 2020-12-16 2022-06-23 Recurium Ip Holdings, Llc Combinations

Also Published As

Publication number Publication date
US20230158048A1 (en) 2023-05-25
CA3174700A1 (en) 2021-11-11
JP2023525022A (ja) 2023-06-14
AU2021268195A1 (en) 2022-09-29
CN115666574A (zh) 2023-01-31
IL297960A (en) 2023-01-01
TW202207920A (zh) 2022-03-01
EP4106760A4 (en) 2024-03-27
WO2021226263A1 (en) 2021-11-11
EP4106760A1 (en) 2022-12-28
KR20230007360A (ko) 2023-01-12

Similar Documents

Publication Publication Date Title
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
MX2022006986A (es) Inhibidores de kras g12c.
MX2023010411A (es) Inhibidores de erbb/btk.
MX2022011750A (es) Combinaciones farmaceuticas para el tratamiento de cancer.
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
MX2021011606A (es) Compuestos dirigidos a prmt5.
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MX2021010321A (es) Compuestos macrociclicos.
MX2023008954A (es) Inhibidores de los receptores erbb.
MX2021012423A (es) Métodos y composiciones para degradación de proteínas específicas.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2022007626A (es) Combinaciones.
MX2020011453A (es) Combinaciones para tratar el cancer.
MX2022009612A (es) Combinacion de bi853520 con farmacos quimioterapeuticos.
MX2022007628A (es) Combinaciones.
MX2021012105A (es) Compuestos de pirrol.
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
MX2022010801A (es) Combinaciones.
MX2023005530A (es) Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon.
MX2022007625A (es) Combinaciones.
MX2022007623A (es) Combinaciones.
MX2022014131A (es) Monoterapias y terapias de combinacion.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12021550323A1 (en) Dendrimer formulations